Core Insights - Silo Pharma has selected the Alphaledger/Simplify Target 12% Distribution Fund as a key part of its real-world asset investment strategy, aiming to diversify its treasury and integrate digital assets [1][3] - The Alphaledger T12 Fund is designed to provide high monthly income through a diversified portfolio of alternative income-generating strategies, operating on the Solana blockchain for efficiency and low costs [2][3] - The investment reflects a broader trend among institutions to incorporate tokenized real-world assets into their balance sheets, enhancing transparency and compliance in financial products [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders and chronic pain [7] - The company is engaged in innovative therapeutic programs, including SPC-15 for PTSD and SP-26 for fibromyalgia, and collaborates with leading universities for research [7] Fund Overview - The Alphaledger T12 Fund is a digital-native investment vehicle that provides access to tokenized real-world assets, leveraging blockchain technology for efficient investment pathways [2][4] - Managed by Alphaledger Investment Management LLC, the fund aims to transform investing through blockchain-powered asset tokenization [5][6]